Breakthrough in Multiple Sclerosis Experimental Treatment: Promising Results from New Anti-CD40L Monoclonal Antibody
Novel Experimental Therapy Shows High Efficacy in MS Management Without Increased Infection Risk
Topline:
A new study reveals that a second-generation anti-CD40L monoclonal antibody significantly reduces disease activity in multiple sclerosis (MS) patients, offering hope for improved treatment without added infection risk.
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.